Opinion of Patients Under Treatment That Meets the Criteria of New Treatment Strategy According to GINA 2006 (EPAGGELIA)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00695357
First received: June 9, 2008
Last updated: April 29, 2009
Last verified: April 2009
  Purpose

Cross-sectional, one visit study. All the data will be collected through questionnaires. Descriptives statistics will be applied to the data. 832 patients will participate to the study and 104 physicians.


Condition
New Strategies
GINA 2006
Patient Opinion

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Opinion of Patients Under Treatment That Meets the Criteria of New Treatment Strategy According to GINA 2006

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Percentage (%) of Asthma treatment satisfaction and control grading [ Time Frame: single visit / once ]

Secondary Outcome Measures:
  • Rate of treatment compliance [ Time Frame: single visit / once ]
  • Patients quality of life under treatment [ Time Frame: single visit / once ]

Estimated Enrollment: 832
Study Start Date: April 2008
Study Completion Date: June 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary care

Criteria

Inclusion Criteria:

  • Patients diagnosed with persistent asthma (GINA 2005) for at least 6 months before entering the study
  • Patients who are under treatment according to the new strategies described in GINA 2006 for at least 3 months before entering the study

Exclusion Criteria:

  • Patients who are not willing to sign the Informed Consent Form
  • COPD Patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00695357

Locations
Greece
Research Site
Aleksandroupoli, Greece
Research Site
Amaliada, Greece
Research Site
Argos, Greece
Research Site
Arta, Greece
Research Site
Athina, Greece
Research Site
Chania, Greece
Research Site
Drama, Greece
Research Site
Githio, Greece
Research Site
Gounari, Greece
Research Site
Imathia, Greece
Research Site
Ioannina, Greece
Research Site
Iraklio, Greece
Research Site
Kalamata, Greece
Research Site
Katerini, Greece
Research Site
Kavala, Greece
Research Site
Komotini, Greece
Research Site
Lamia, Greece
Research Site
Larisa, Greece
Research Site
Nafpaktos, Greece
Research Site
Neapoli, Greece
Research Site
Patra, Greece
Research Site
Pirgos, Greece
Research Site
Rafina, Greece
Research Site
Serres, Greece
Research Site
Sparti, Greece
Research Site
Thessaloniki, Greece
Research Site
Trikala, Greece
Research Site
Tripoli, Greece
Research Site
Veria, Greece
Research Site
Volos, Greece
Research Site
Xalkida, Greece
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Zachariadis Manolis, MD Euroclinic, Athens, Greece
  More Information

No publications provided

Responsible Party: Pontikis Panagiotis, MD, Medical and Regulatory Director, AstraZeneca Greece, AstraZeneca SA, Greece
ClinicalTrials.gov Identifier: NCT00695357     History of Changes
Other Study ID Numbers: NIS-RGR-DUM-2008/1
Study First Received: June 9, 2008
Last Updated: April 29, 2009
Health Authority: Greece: National Organization of Medicines

Keywords provided by AstraZeneca:
Asthma treatment
GINA 2006
patient perception

ClinicalTrials.gov processed this record on October 01, 2014